<DOC>
	<DOCNO>NCT01233453</DOCNO>
	<brief_summary>This prospective , randomize , multi center study . Approximately 2700 patient enter study randomize 2:1 basis . Patients meet eligibility criterion randomize everolimus elute XIENCE-V® , XIENCE-Prime® PROMUS® stent versus Biolimus A9 elute NOBORI® stent . Patients follow 5 year .</brief_summary>
	<brief_title>Comparison Everolimus Eluting With Biolimus A9 Eluting Stent</brief_title>
	<detailed_description>The main objective study head head comparison everolimus elute XIENCE-V ® , XIENCE-Prime® PROMUS ® stent biolimus A9 elute NOBORI® stent order observe whether difference clinical outcome stent real world / all-comer situation . Clinical outcome stent assess composite end point : cardiac death , non fatal myocardial infarction target vessel revascularization . Endpoints The primary end point study composite safety ( cardiac death , non fatal myocardial infarction ) efficacy ( target vessel revascularization ) 12 month . The secondary end point study : A ) The combine endpoint cardiac death , non fatal myocardial infarction , ischemic driven target lesion revascularization ( TLR ) rate 12 month follow-up . B ) Incidence Cardiac Death Post-Procedural ( &gt; 48h ) MI rate 12 month , 3 5 year C ) Target lesion revascularization 12 month , 3 5 year D ) The combine endpoint cardiac death , non fatal myocardial infarction , target vessel revascularization ( TVR ) rate 3 5 year follow-up . E ) The combine endpoint cardiac death , non fatal myocardial infarction target vessel revascularization 12 month , 3 5 year STEMI patient , small vessel ( &lt; 2.75 mm RVD ) , long lesion ( &gt; 20 mm ) , female patient , DM patient octogenarian . F ) Procedural performance index procedure , measure ability cross lesion designate DES stent . G ) Incidence definite probable stent thrombosis 12 month , 3 5 year time . H ) Incidence definite , probable possible stent thrombosis 12 month , 3 and5 year time . Overview study This prospective , randomize , multi center study . Approximately 2700 patient enter study randomize 2:1 basis . Patients meet eligibility criterion randomize everolimus elute XIENCE-V® , XIENCE-Prime® PROMUS® stent versus Biolimus A9 elute NOBORI® stent . Patients follow 5 year . The study population consist approximately 2700 patient ( 1 year enrollment consecutive all-comers refer percutaneous coronary intervention ( PCI ) coronary artery by-pass graft lesion ) . Patients must meet eligibility criterion inclusion study . Randomization perform use close envelope code N NOBORI stent code E Everolimus elute stent . Duration study The enrollment phase start January 2009 stop December 2010 . The followup phase last till December 2015 .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . The patient least 18 year old life expectancy 5 year . 2 . Patient undergoes PCI procedure indication accord Dutch European guideline 3 . Patient willing comply extend followup period 2 5 year ( secondary endpoint ) 4 . Reference lumen diameter treat vessel 2.0 4.0 mm . 5 . Informed consent 1 . Expected nonadherence dual antiplatelet therapy 1 year ( e.g : know allergy ASA thienopyridines like clopidogrel ) 2 . Expected major surgery within 30 day ( patient receive bare metal stent ) 3 . Cardiogenic shock ( Kilip class 4 ) 4 . Previous PCI procedure implantation drug elute stent within 1 year . 5 . Expected loss follow 6 . Enrollment investigative stent study different stent 7 . Inability implant Nobori XienceV / Promus stent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>